2022
Development and validation of an automated algorithm for end point adjudication for a large U.S. national registry
Friedman DJ, Pierre D, Wang Y, Gambone L, Koutras C, Segawa C, Farb A, Vemulapalli S, Varosy PD, Masoudi FA, Lansky A, Curtis JP, Freeman JV. Development and validation of an automated algorithm for end point adjudication for a large U.S. national registry. American Heart Journal 2022, 254: 102-111. PMID: 36007567, DOI: 10.1016/j.ahj.2022.08.006.Peer-Reviewed Original ResearchConceptsEnd point adjudicationCEC adjudicationEnd pointLarge registriesClinical trialsNational Cardiovascular Data RegistryMajor vascular complicationsU.S. National RegistryPost-discharge eventsAgreement rateMajor bleedingNeurologic eventsVascular complicationsNational registryEvent adjudicationData registryRegistryCommittee's evaluationsPercent agreementGold standardAgreement thresholdHospitalTrialsFurther confirmationBleeding
2021
Safety and efficacy of dedicated guidewire, microcatheter, and guide catheter extension technologies for chronic total coronary occlusion revascularization: Primary results of the Teleflex Chronic Total Occlusion Study
Kandzari DE, Alaswad K, Jaffer FA, Brilakis E, Croce K, Kearney K, Spaedy A, Yeh R, Thompson C, Nicholson W, Wyman RM, Riley R, Lansky A, Buller C, Karmpaliotis D. Safety and efficacy of dedicated guidewire, microcatheter, and guide catheter extension technologies for chronic total coronary occlusion revascularization: Primary results of the Teleflex Chronic Total Occlusion Study. Catheterization And Cardiovascular Interventions 2021, 99: 263-270. PMID: 34582080, DOI: 10.1002/ccd.29962.Peer-Reviewed Original ResearchConceptsMyocardial infarctionGuidewire recanalizationProcedural successCatheter extensionChronic total coronary occlusion revascularizationChronic total occlusion (CTO) percutaneous revascularizationFavorable procedural successGuide catheter extensionHigher lesion complexityHospital cardiac deathProspective registration studyTotal Occlusion StudyTarget lesion revascularizationPrevalence of diabetesPrior myocardial infarctionSingle-arm studyTIMI grade 2Femoral arterial accessJ-CTO scorePrevious bypass surgeryNon-CTO PCIHospital MACELesion revascularizationCTO revascularizationHemodynamic instability
2020
Does the operator's sex matter? An analysis based on the national interventional cardiology registry.
Lanocha M, Lansky A, Siudak Z, Włodarczak A, Tarchalski J, Malinowski KP, Laskowski W, Sikora T, Radziszewska E, Dolecka-Ślusarczyk M, Wojakowski W, Bartuś S, Grygier M, Tokarek T, Dudek D, Lesiak M. Does the operator's sex matter? An analysis based on the national interventional cardiology registry. Kardiologia Polska 2020, 78: 1221-1226. PMID: 33146499, DOI: 10.33963/kp.15665.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionPractice patternsOutcomes of PCIInterventional cardiologyInterventional Cardiology RegistryCardiovascular risk factorsAcute coronary syndromeSingle-vessel diseaseCoronary artery interventionInvasive cardiology proceduresSex matterMale operatorsCardiology RegistryCoronary syndromeCoronary interventionArtery interventionMore patientsClinical outcomesMain indicationsNational registryRisk factorsMedian numberContrast dosesLow prevalenceHigh doses
2019
Validation of the all-comers design: Results of the TARGET-AC substudy
G Toth G, Lansky A, Baumbach A, Kelbæk H, van Royen N, Holmvang L, Janssens L, Brugaletta S, Barbato E, Maillard L, Kiemeneij F, Naber CK, Pucher F, Laursen PN, Ameloot K, Robles C, Milkas A, Sevilla J, Jensen C, Wijns W. Validation of the all-comers design: Results of the TARGET-AC substudy. American Heart Journal 2019, 221: 148-154. PMID: 31924299, DOI: 10.1016/j.ahj.2019.10.019.Peer-Reviewed Original ResearchConceptsComers designRisk factorsNon-ST elevation acute coronary syndromeElevation acute coronary syndromeNER groupReal-world clinical practiceGroup more patientsInternational multicentre registrySignificant valvular diseaseST-elevation infarctionAcute coronary syndromeChronic total occlusionWorld clinical practiceLow inclusion rateMulticentre registryThrombotic stenosisCoronary syndromePrimary PCIStable anginaAngiographic parametersComers populationPatient demographicsStable patientsStudy nursesMore patientsPredictors of In-Hospital Mortality after Transcatheter Aortic Valve Implantation
Krittanawong C, Kumar A, Wang Z, Johnson KW, Rastogi U, Narasimhan B, Kaplin S, Virk HUH, Baber U, Tang W, Lansky AJ, Stone GW. Predictors of In-Hospital Mortality after Transcatheter Aortic Valve Implantation. The American Journal Of Cardiology 2019, 125: 251-257. PMID: 31759517, DOI: 10.1016/j.amjcard.2019.10.014.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve implantationBaseline heart failureAortic valve implantationHeart failureAdditional independent predictorsHospital mortalityEjection fractionIndependent predictorsValve implantationPresence of HFReduced ejection fractionSevere aortic stenosisIn-Hospital MortalityPredictors of mortalityPotential baseline confoundersAortic valve stenosisICD-9 codesAbsence of depressionTAVI patientsHF patientsAortic stenosisValve stenosisLiver diseaseMultivariable analysisPatient selectionUse of Impella heart pump for management of women with peripartum cardiogenic shock
Elkayam U, Schäfer A, Chieffo A, Lansky A, Hall S, Arany Z, Grines C. Use of Impella heart pump for management of women with peripartum cardiogenic shock. Clinical Cardiology 2019, 42: 974-981. PMID: 31436333, PMCID: PMC6788473, DOI: 10.1002/clc.23249.Peer-Reviewed Original ResearchConceptsLeft ventricular assist deviceMechanical circulatory supportCardiogenic shockPeripartum cardiomyopathyImpella deviceCatheter-based ventricular assist device registryVeno-arterial extracorporeal membrane oxygenationDurable left ventricular assist devicePercutaneous mechanical circulatory supportInotropes/vasopressorsSevere LV dysfunctionUse of ImpellaSevere heart failureManagement of womenMean ejection fractionExtracorporeal membrane oxygenationNative heart functionVentricular assist deviceHannover Medical SchoolLV dysfunctionEjection fractionHeart failureMembrane oxygenationCirculatory supportMean ageThe Clinical Utility of a Precision Medicine Blood Test Incorporating Age, Sex, and Gene Expression for Evaluating Women with Stable Symptoms Suggestive of Obstructive Coronary Artery Disease: Analysis from the PRESET Registry
Gul B, Lansky A, Budoff MJ, Sharp D, Maniet B, Herman L, Kuo JZ, Huang L, Monane M, Ladapo JA. The Clinical Utility of a Precision Medicine Blood Test Incorporating Age, Sex, and Gene Expression for Evaluating Women with Stable Symptoms Suggestive of Obstructive Coronary Artery Disease: Analysis from the PRESET Registry. Journal Of Women's Health 2019, 28: 728-735. PMID: 30653377, PMCID: PMC6537117, DOI: 10.1089/jwh.2018.7203.Peer-Reviewed Original ResearchConceptsObstructive coronary artery diseaseCoronary artery diseaseFurther cardiac evaluationCardiac evaluationArtery diseaseClinical utilityStable obstructive coronary artery diseaseMajor adverse cardiac eventsMedian age 57 yearsMedian body mass indexAdverse cardiac eventsAge 57 yearsManagement of womenBody mass indexCommunity-based registryPrimary care practicesPrecision medicine testsGene expression scoreCardiac referralHypertension presentSymptoms SuggestiveCardiac eventsClinical characteristicsMass indexStudy cohort
2018
Sex disparities in acute myocardial infarction care and outcomes
Gul B, Kozuma K, Haimi I, Zhao W, Simonton C, Ying S, Buda A, Mehta S, Baumbach A, Lansky A. Sex disparities in acute myocardial infarction care and outcomes. Catheterization And Cardiovascular Interventions 2018, 92: e341-e347. PMID: 29745453, DOI: 10.1002/ccd.27622.Peer-Reviewed Original ResearchMeSH KeywordsAgedChinaClinical Trials as TopicFemaleHealthcare DisparitiesHemorrhageHumansJapanMaleMiddle AgedNon-ST Elevated Myocardial InfarctionPercutaneous Coronary InterventionProduct Surveillance, PostmarketingRegistriesRetrospective StudiesRisk AssessmentRisk FactorsSex FactorsST Elevation Myocardial InfarctionStentsTime FactorsTreatment OutcomeUnited StatesConceptsMajor adverse cardiac eventsAcute myocardial infarctionPercutaneous coronary interventionTarget vessel failureCause mortalityXience V stentMajor bleedingUS patientsHigher major adverse cardiac eventsSetting of AMIContemporary percutaneous coronary interventionAcute myocardial infarction careDevice-specific outcomesAdverse cardiac eventsMyocardial infarction carePost-market registryCause deathCardiac eventsCoronary interventionMultivariable analysisFemale sexMyocardial infarctionPatient levelSex disparitiesPatientsA prospective, multi‐center study of the chocolate balloon in femoropopliteal peripheral artery disease: The Chocolate BAR registry
Mustapha JA, Lansky A, Shishehbor M, McClure J, Johnson S, Davis T, Makam P, Crowder W, Konstantino E, Attaran RR, Investigators T. A prospective, multi‐center study of the chocolate balloon in femoropopliteal peripheral artery disease: The Chocolate BAR registry. Catheterization And Cardiovascular Interventions 2018, 91: 1144-1148. PMID: 29513389, DOI: 10.1002/ccd.27565.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonEquipment DesignFemaleFemoral ArteryHumansMaleMiddle AgedPeripheral Arterial DiseasePopliteal ArteryProduct Surveillance, PostmarketingProspective StudiesRegistriesRisk FactorsStentsTime FactorsTreatment OutcomeUnited StatesVascular Access DevicesVascular PatencyConceptsTarget lesion revascularizationPrimary endpointFemoropopliteal peripheral artery diseaseSymptomatic peripheral arterial diseaseExcellent procedural outcomesLower dissection ratePeripheral arterial diseasePeripheral artery diseaseAcute procedural successLong-term outcomesPost-market registryMulti-center studyAngioplasty balloon catheterPercutaneous transluminal angioplasty balloon catheterRutherford classCause mortalityLesion revascularizationMajor amputationArtery diseaseArterial diseaseProcedural successUnplanned amputationBalloon catheterProcedural outcomesProcedure successAcute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry.
Baumbach A, Zaman A, West NEJ, O'Kane P, Egred M, Johnson T, Wheatcroft S, Bowles R, de Belder A, Bouras G, Lansky A, Hill J, Mathur A, de Belder MA, Banning AP. Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry. EuroIntervention 2018, 13: 1554-1560. PMID: 29131802, DOI: 10.4244/eij-d-17-00886.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAcute Coronary SyndromeAdultClinical Decision-MakingCoronary Artery DiseaseCoronary ThrombosisFemaleHumansMaleMiddle AgedPatient SelectionPercutaneous Coronary InterventionPractice Patterns, Physicians'Product Surveillance, PostmarketingProspective StudiesProsthesis DesignRegistriesRisk FactorsTime FactorsTreatment OutcomeUnited KingdomConceptsBioresorbable vascular scaffoldDe novo coronary lesionsOne-year clinical outcomesIndependent clinical events committeeMajor adverse cardiac eventsAbsorb bioresorbable vascular scaffoldCareful implantation techniqueAdverse cardiac eventsNovo coronary lesionsTarget lesion failureAcute coronary syndromeClinical events committeeB2/CCareful patient selectionContemporary drug-eluting stentsDrug-eluting stentsVascular scaffoldsSmall vessel sizeDefinite STCoronary syndromeLesion failureCardiac eventsPatient ageReal-world practiceBVS implantation
2016
Significance of prior percutaneous revascularisation in patients with acute coronary syndromes: insights from the prospective PROSPECT registry.
Iñiguez A, Brener SJ, Jiménez VA, Maehara A, Mintz GS, Xu K, Weisz G, Lansky AJ, De Bruyne B, Serruys PW, Stone GW. Significance of prior percutaneous revascularisation in patients with acute coronary syndromes: insights from the prospective PROSPECT registry. EuroIntervention 2016, 11: 1468-74. PMID: 27107311, DOI: 10.4244/eijv11i13a285.Peer-Reviewed Original ResearchConceptsPrior PCIPrior percutaneous coronary interventionMajor adverse cardiac eventsACS patientsAcute coronary syndrome patientsAdverse cardiac eventsAcute coronary syndromeChronic kidney diseaseCoronary syndrome patientsHigh-risk featuresCongestive heart failureIntravascular ultrasound findingsPercutaneous coronary interventionPrior myocardial infarctionCoronary syndromeCardiac eventsCoronary interventionCardiac deathHeart failurePercutaneous revascularisationKidney diseaseMyocardial infarctionUltrasound findingsIndependent associationMultivariable model
2015
Safety and efficacy of a novel abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent for the treatment of de novo coronary lesions: Two‐year results from a prospective patient‐level pooled analysis of TARGET trials
Gao Z, Zhang R, Xu B, Yang Y, Ma C, Li H, Chen S, Han Y, Yuan Z, Lansky AJ, Guan C, Leon MB, Gao R, Investigators F. Safety and efficacy of a novel abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent for the treatment of de novo coronary lesions: Two‐year results from a prospective patient‐level pooled analysis of TARGET trials. Catheterization And Cardiovascular Interventions 2015, 85: 734-743. PMID: 25678281, DOI: 10.1002/ccd.25861.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedCardiovascular AgentsChinaCoronary Artery DiseaseDrug-Eluting StentsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPolymersProspective StudiesProsthesis DesignRandomized Controlled Trials as TopicRegistriesRisk FactorsSirolimusTime FactorsTreatment OutcomeConceptsTarget lesion failureFIREHAWK stentStent thrombosisCoronary lesionsMyocardial infarctionNovel abluminal groove-filled biodegradable polymer sirolimus-eluting stentDe novo native coronary lesionsBiodegradable polymer sirolimus-eluting stentsDe novo coronary lesionsPatient-level pooled analysisTarget vessel myocardial infarctionNew drug-eluting stentsNative coronary lesionsNovo coronary lesionsProbable stent thrombosisTarget lesion revascularizationVessel myocardial infarctionSirolimus-eluting stentsPatient-level analysisPatient-level dataLong-term safetyDrug-eluting stentsTwo-year resultsObjective performance criteriaLesion revascularization
2014
Will this trial change my practice? TASTE - a randomised registry on thrombus aspiration in primary PCI with a 30-day endpoint.
Behan MW, Lansky AJ, Jolly S, Baumbach A. Will this trial change my practice? TASTE - a randomised registry on thrombus aspiration in primary PCI with a 30-day endpoint. EuroIntervention 2014, 10: 406-7. PMID: 25042270, DOI: 10.4244/eijv10i3a68.Peer-Reviewed Original Research
2012
Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doing.
Saito S, Nakamura S, Fujii K, Nakamura M, Isshiki T, Hirayama H, Kikuchi T, Fujita H, Nonogi H, Mitsudo K, Kimura T, Igarashi K, Saito K, Lansky AJ, Stone GW, Honda Y, Waseda K, Fitzgerald PJ, Sudhir K. Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doing. Journal Of Invasive Cardiology 2012, 24: 444-50. PMID: 22954564.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsDrug-eluting stentsSegment late lossJapan RegistryLate lossUS patientsEES groupPrimary endpointSingle-arm multicenter studySecond-generation drug-eluting stentsFirst-generation drug-eluting stentsLower late lossTarget vessel failureAdverse cardiac eventsMid-term resultsCardiac eventsPES groupMulticenter studyJapanese patientsNeointimal volumeApposition ratePatientsStudy aimClinical programsComparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial
Palmerini T, Caixeta A, Genereux P, Cristea E, Lansky A, Mehran R, Dangas G, Lazar D, Sanchez R, Fahy M, Xu K, Stone GW. Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial. American Heart Journal 2012, 163: 383-391.e5. PMID: 22424008, DOI: 10.1016/j.ahj.2011.11.010.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionCardiac Surgery (SYNTAX) scoreNet reclassification improvementAcute coronary syndromePrognostic risk scoreMyocardial infarctionRisk scoreAngiographic variablesVessel revascularizationCardiac mortalityCoronary syndromeEnd pointSurgery scoreSegment elevation acute coronary syndromesUrgent Intervention Triage Strategy (ACUITY) trialAcute Coronary Events (GRACE) scoreElevation acute coronary syndromeNew risk stratification scoreEjection fraction (ACEF) scoreIschemic end pointsMyocardial Infarction (TIMI) scoreTarget vessel revascularizationRisk stratification scoresCoronary artery diseaseMost end points
2011
Initial experience with a dedicated coronary re‐entry device for revascularization of chronic total occlusions
Whitlow PL, Lombardi WL, Araya M, Wyman R, Torres H, Dauvergne C, Tsuchikane E, Lansky A, Thompson CA. Initial experience with a dedicated coronary re‐entry device for revascularization of chronic total occlusions. Catheterization And Cardiovascular Interventions 2011, 80: 807-813. PMID: 22121076, DOI: 10.1002/ccd.23417.Peer-Reviewed Original ResearchConceptsChronic total coronary occlusionsDistal true lumenRe-entry deviceTrue lumenAntegrade guidewireWire entrapmentTIMI 3 flowTotal coronary occlusionChronic total occlusionGuidewire penetrationConsecutive CTO lesionsPrimary endpointProspective registryClinical improvementSuccessful recanalizationCoronary perforationMajor complicationsCTO lesionsCoronary occlusionCTO interventionTotal occlusionLesion characteristicsSubintimal spaceRetrograde techniqueInitial experience
2009
Clinical and angiographic outcomes with an everolimus‐eluting stent in large coronary arteries: The SPIRIT III 4.0 mm registry
Gordon PC, Applegate RJ, Hermiller JB, Weinsier SB, Doostzadeh J, Cao S, Sudhir K, Lansky AJ, Stone GW. Clinical and angiographic outcomes with an everolimus‐eluting stent in large coronary arteries: The SPIRIT III 4.0 mm registry. Catheterization And Cardiovascular Interventions 2009, 75: 179-186. PMID: 19877267, DOI: 10.1002/ccd.22259.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelPredictive Value of TestsProspective StudiesRegistriesRisk AssessmentSingle-Blind MethodSirolimusThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsMajor adverse cardiac eventsTarget vessel failureSegment late lossSPIRIT III trialLarge coronary arteriesPaclitaxel-eluting stentsLate lossCoronary arteryIII trialsXIENCE VDe novo native coronary artery lesionsNovo native coronary artery lesionsNative coronary artery lesionsPE armSPIRIT IIIAdverse cardiac eventsCoronary artery lesionsAdverse clinical eventsAngiographic late lossEES patientsNoninferior ratesPrimary endpointAngiographic outcomesArtery lesionsCardiac eventsSafety and Efficacy of Drug-Eluting and Bare Metal Stents
Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and Efficacy of Drug-Eluting and Bare Metal Stents. Circulation 2009, 119: 3198-3206. PMID: 19528338, DOI: 10.1161/circulationaha.108.826479.Peer-Reviewed Original ResearchConceptsBare metal stentsDrug-eluting stentsTarget vessel revascularizationMyocardial infarctionVessel revascularizationObservational studyMetal stentsEfficacy end pointTotal patientsOverall mortalityDrug-ElutingDES useLabel indicationsLabel useResidual confoundingBMS useRCTsPatientsDrug AdministrationInfarctionRevascularizationEnd pointMortality dataComparable reductionStents
2007
Clinical Outcomes After Heterogeneous Overlap Stenting With Drug-Eluting Stents and Bare-Metal Stents for de Novo Coronary Artery Narrowings
Aoki J, Kirtane AJ, Dangas GD, Lansky AJ, Morales A, Kimura M, Kim YH, Moussa I, Weisz G, Kreps EM, Collins M, Frankin-Bond T, Stone GW, Moses JW, Leon MB, Mehran R. Clinical Outcomes After Heterogeneous Overlap Stenting With Drug-Eluting Stents and Bare-Metal Stents for de Novo Coronary Artery Narrowings. The American Journal Of Cardiology 2007, 101: 58-62. PMID: 18157966, DOI: 10.1016/j.amjcard.2007.07.049.Peer-Reviewed Original ResearchConceptsDrug-eluting stentsBare metal stentsClinical outcomesTarget vessel revascularization rateMultiple drug-eluting stentsAcute stent thrombosisVessel revascularization rateDe novo lesionsTarget vessel revascularizationPercutaneous coronary interventionCoronary artery narrowingImplanted stent diameterNovo lesionsProspective registryRevascularization ratesVessel revascularizationBMS implantationCoronary interventionDES implantationConsecutive patientsArtery narrowingStent thrombosisMyocardial infarctionStent restenosisStent diameterShort- and Long-Term Outcomes After Stent-Assisted Percutaneous Treatment of Saphenous Vein Grafts in the Drug-Eluting Stent Era
Pucelikova T, Mehran R, Kirtane AJ, Kim YH, Fahy M, Weisz G, Lansky AJ, Moussa I, Gray WA, Collins MB, Kodali SK, Stone GW, Moses JW, Leon MB, Dangas G. Short- and Long-Term Outcomes After Stent-Assisted Percutaneous Treatment of Saphenous Vein Grafts in the Drug-Eluting Stent Era. The American Journal Of Cardiology 2007, 101: 63-68. PMID: 18157967, DOI: 10.1016/j.amjcard.2007.07.048.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCoronary AngiographyCoronary Artery BypassFemaleFollow-Up StudiesGraft Occlusion, VascularHumansMaleMultivariate AnalysisMyocardial InfarctionMyocardiumNecrosisPaclitaxelProspective StudiesProsthesis DesignRegistriesRetreatmentSaphenous VeinSirolimusStentsThrombosisConceptsMajor adverse cardiac eventsAdverse cardiac eventsPercutaneous coronary interventionDrug-eluting stentsSVG lesionsVessel revascularizationCardiac eventsCoronary interventionPercutaneous treatmentMyocardial infarctionStent-assisted percutaneous coronary interventionSaphenous vein graft lesionsNative vessel diseasePeriprocedural myocardial necrosisTarget lesion revascularizationTarget vessel revascularizationSaphenous vein graftsVein graft lesionsPresence of thrombusEmbolic protection devicesHigh-risk subgroupsLong-term outcomesContemporary clinical practiceLesion revascularizationStent thromboses